Lopinavir Main Page

Medical Advocates
Lopinavir/Ritonavir (Kaletra/Aluvia)

Main Page

New and Noteworthy
Journal Papers/Abstracts/ Commentaries
Conference Abstracts and Posters
Pediatric Indications
Perinatal Data
Therapeutic Monitoring
Product Information
Protease Inhibitors: General Data
Database of ARV Drug Interactions

Main New/Newsworthy Drugs Home

This web page is best viewed by using INTERNET EXPLORER
Last Update: February 05, 2012
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

New and Noteworthy

January 2012

A WEEK-IN REVIEW FEATURED REPORT
New strategies in the optimisation of lopinavir/ritonavir doses in human immunodeficiency virus-
infected patients
López Aspiroz E, Cabrera Figueroa SE, et al Enferm Infecc Microbiol Clin. 2012 Jan 24.

Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based
antitubercular treatment in HIV-infected children.
Zhang C, McIlleron H, Ren Y, et al Antivir Ther. 2012;17(1):25-33.

A WEEK-IN-REVIEW FEATURED REPORT
Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with
lopinavir/ritonavir as their first protease inhibitor.
Barber TJ, Harrison L, Asboe D, et al J Antimicrob Chemother. 2012 Jan 17

Main New/Newsworthy Drugs Home

Lopinavir Main Page